🇺🇸 ChAdOx1 nCoV-19 in United States

44 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Back Pain — 5 reports (11.36%)
  2. Dry Skin — 5 reports (11.36%)
  3. Nasopharyngitis — 5 reports (11.36%)
  4. Skin Ulcer — 5 reports (11.36%)
  5. Abdominal Distension — 4 reports (9.09%)
  6. Constipation — 4 reports (9.09%)
  7. Diarrhoea — 4 reports (9.09%)
  8. Gastrointestinal Disorder — 4 reports (9.09%)
  9. Neuropathy Peripheral — 4 reports (9.09%)
  10. Rash Papular — 4 reports (9.09%)

Source database →

Other Immunology / Infectious Disease approved in United States

Frequently asked questions

Is ChAdOx1 nCoV-19 approved in United States?

ChAdOx1 nCoV-19 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for ChAdOx1 nCoV-19 in United States?

EuBiologics Co.,Ltd is the originator. The local marketing authorisation holder may differ — check the official source linked above.